News | December 24, 2023
Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The cognitively operated system is a mother patent invention, first launched in India
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Subscribe To Our Newsletter & Stay Updated
